© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 Oxford University Press
NEWS |
Biomarker Boom Slowed by Validation Concerns
| The first 10% of the full text of this article appears below. |
By many accounts, the brave new worlds of genomics and proteomics—and their accompanying technologies—have ushered in a new era of cancer biomarker research. Researchers in cancer detection, diagnosis, and treatment all have a vested interest in discovering these proteins and small molecules that are telltale signs of early cancer, characteristics that make a type of cancer unique, or markers that predict whether a patient will respond to a given treatment. As a result, the number of uses for cancer biomarkers has expanded at a rapid pace.
"Cancer biomarkers are practically pouring out of research laboratories," said Bruce Zetter, Ph.D., Charles Nowiszewski Professor of Cancer Biology at Boston's Children's Hospital.
But as researchers and oncologists use and develop technology to uncover a
wealth of markers that may ultimately affect cancer detection and diagnostics,
many argue that, at least for now, the biomarker research engine is stuck in
neutral. What
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Vasmatzis, E. W. Klee, D. M. Kube, T. M. Therneau, and F. Kosari Quantitating tissue specificity of human genes to facilitate biomarker discovery Bioinformatics, June 1, 2007; 23(11): 1348 - 1355. [Abstract] [Full Text] [PDF]
|
|